These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 16203819)

  • 1. Radioimmunotherapy with [131I]cG250 in patients with metastasized renal cell cancer: dosimetric analysis and immunologic response.
    Brouwers AH; Buijs WC; Mulders PF; de Mulder PH; van den Broek WJ; Mala C; Oosterwijk E; Boerman OC; Corstens FH; Oyen WJ
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7178s-7186s. PubMed ID: 16203819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinoma.
    Brouwers AH; Mulders PF; de Mulder PH; van den Broek WJ; Buijs WC; Mala C; Joosten FB; Oosterwijk E; Boerman OC; Corstens FH; Oyen WJ
    J Clin Oncol; 2005 Sep; 23(27):6540-8. PubMed ID: 16170161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intratumoral distribution of two consecutive injections of chimeric antibody G250 in primary renal cell carcinoma: implications for fractionated dose radioimmunotherapy.
    Steffens MG; Boerman OC; Oyen WJ; Kniest PH; Witjes JA; Oosterhof GO; van Leenders GJ; Debruyne FM; Corstens FH; Oosterwijk E
    Cancer Res; 1999 Apr; 59(7):1615-9. PubMed ID: 10197637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with (131)I or (111)In: an intrapatient comparison.
    Brouwers AH; Buijs WC; Oosterwijk E; Boerman OC; Mala C; De Mulder PH; Corstens FH; Mulders PF; Oyen WJ
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3953S-60S. PubMed ID: 14506194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
    Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
    J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer.
    Divgi CR; O'Donoghue JA; Welt S; O'Neel J; Finn R; Motzer RJ; Jungbluth A; Hoffman E; Ritter G; Larson SM; Old LJ
    J Nucl Med; 2004 Aug; 45(8):1412-21. PubMed ID: 15299069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250.
    Steffens MG; Boerman OC; Oosterwijk-Wakka JC; Oosterhof GO; Witjes JA; Koenders EB; Oyen WJ; Buijs WC; Debruyne FM; Corstens FH; Oosterwijk E
    J Clin Oncol; 1997 Apr; 15(4):1529-37. PubMed ID: 9193349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dosimetric analysis of 177Lu-cG250 radioimmunotherapy in renal cell carcinoma patients: correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on 111In-cG250 imaging.
    Stillebroer AB; Zegers CM; Boerman OC; Oosterwijk E; Mulders PF; O'Donoghue JA; Visser EP; Oyen WJ
    J Nucl Med; 2012 Jan; 53(1):82-9. PubMed ID: 22159179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250.
    Steffens MG; Boerman OC; de Mulder PH; Oyen WJ; Buijs WC; Witjes JA; van den Broek WJ; Oosterwijk-Wakka JC; Debruyne FM; Corstens FH; Oosterwijk E
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3268s-3274s. PubMed ID: 10541374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial experience with high-dose radioimmunotherapy of metastatic medullary thyroid cancer using 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen MAb and AHSCR.
    Juweid ME; Hajjar G; Stein R; Sharkey RM; Herskovic T; Swayne LC; Suleiman S; Pereira M; Rubin AD; Goldenberg DM
    J Nucl Med; 2000 Jan; 41(1):93-103. PubMed ID: 10647610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective open-label single-arm phase II study of chimeric monoclonal antibody cG250 in advanced renal cell carcinoma patients.
    Varga Z; de Mulder P; Kruit W; Hegele A; Hofmann R; Lamers C; Warnaar S; Mala C; Ullrich S; Mulders P
    Folia Biol (Praha); 2003; 49(2):74-7. PubMed ID: 12779016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic model of iodine-131-G250 antibody in renal cell carcinoma patients.
    Loh A; Sgouros G; O'Donoghue JA; Deland D; Puri D; Capitelli P; Humm JL; Larson SM; Old LJ; Divgi CR
    J Nucl Med; 1998 Mar; 39(3):484-9. PubMed ID: 9529296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody.
    Denardo SJ; O'Grady LF; Richman CM; Goldstein DS; O'Donnell RT; Denardo DA; Kroger LA; Lamborn KR; Hellström KE; Hellström I; Denardo GL
    Anticancer Res; 1997; 17(3B):1745-51. PubMed ID: 9179228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Technology evaluation: WX-G250, Wilex/Ludwig Institute for Cancer Research.
    Kennett RH
    Curr Opin Mol Ther; 2003 Feb; 5(1):70-5. PubMed ID: 12669474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
    DeNardo GL; DeNardo SJ; Shen S; DeNardo DA; Mirick GR; Macey DJ; Lamborn KR
    J Nucl Med; 1999 Aug; 40(8):1317-26. PubMed ID: 10450684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial.
    Kraeber-Bodéré F; Rousseau C; Bodet-Milin C; Ferrer L; Faivre-Chauvet A; Campion L; Vuillez JP; Devillers A; Chang CH; Goldenberg DM; Chatal JF; Barbet J
    J Nucl Med; 2006 Feb; 47(2):247-55. PubMed ID: 16455630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of 131I-chimeric(ch) TNT-1/B monoclonal antibody for the treatment of advanced colon cancer.
    Street HH; Goris ML; Fisher GA; Wessels BW; Cho C; Hernandez C; Zhu HJ; Zhang Y; Nangiana JS; Shan JS; Roberts K; Knox SJ
    Cancer Biother Radiopharm; 2006 Jun; 21(3):243-56. PubMed ID: 16918301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma.
    Stillebroer AB; Boerman OC; Desar IM; Boers-Sonderen MJ; van Herpen CM; Langenhuijsen JF; Smith-Jones PM; Oosterwijk E; Oyen WJ; Mulders PF
    Eur Urol; 2013 Sep; 64(3):478-85. PubMed ID: 22980441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma.
    Divgi CR; Scott AM; Dantis L; Capitelli P; Siler K; Hilton S; Finn RD; Kemeny N; Kelsen D; Kostakoglu L
    J Nucl Med; 1995 Apr; 36(4):586-92. PubMed ID: 7699446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: clinical phase I/II trials.
    Chen ZN; Mi L; Xu J; Song F; Zhang Q; Zhang Z; Xing JL; Bian HJ; Jiang JL; Wang XH; Shang P; Qian AR; Zhang SH; Li L; Li Y; Feng Q; Yu XL; Feng Y; Yang XM; Tian R; Wu ZB; Leng N; Mo TS; Kuang AR; Tan TZ; Li YC; Liang DR; Lu WS; Miao J; Xu GH; Zhang ZH; Nan KJ; Han J; Liu QG; Zhang HX; Zhu P
    Int J Radiat Oncol Biol Phys; 2006 Jun; 65(2):435-44. PubMed ID: 16690431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.